NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 866.8 DKK | -1.35% |
|
+0.48% | +24.17% |
| Apr. 25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
| Sales 2024 * | 287B 41.34B | Sales 2025 * | 346B 49.73B | Capitalization | 3,867B 556B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 14.9B | Net income 2025 * | 125B 17.96B | EV / Sales 2024 * | 13.5 x |
| Net Debt 2024 * | 23.85B 3.43B | Net cash position 2025 * | 348M 50.11M | EV / Sales 2025 * | 11.2 x |
| P/E ratio 2024 * |
37.5
x | P/E ratio 2025 * |
30.9
x | Employees | 63,845 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.62% | Free-Float | 70.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
More news
| 1 day | -1.35% | ||
| 1 week | +0.48% | ||
| Current month | -1.65% | ||
| 1 month | -3.10% | ||
| 3 months | +19.74% | ||
| 6 months | +25.19% | ||
| Current year | +24.17% |
1 week
850.70
894.10
1 month
845.10898.00
Current year
688.80932.00
1 year
504.40932.00
3 years
224.55932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 192 M€ | +11.66% | ||
| 10.45% | 5 M€ | +7.05% | ||
| 5.40% | 18 M€ | +3.79% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 866.8 | -1.35% | 2,439,240 |
| 24-04-24 | 878.7 | -1.41% | 1,877,505 |
| 24-04-23 | 891.3 | +1.83% | 1,866,811 |
| 24-04-22 | 875.3 | +1.05% | 2,031,675 |
| 24-04-19 | 866.2 | +0.41% | 1,938,339 |
Delayed Quote Nasdaq Copenhagen, April 25, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
866.8
DKK
Average target price
904.2
DKK
Spread / Average Target
+4.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B | |
| +2.07% | 123B |
- Stock Market
- Equities
- NOVO B Stock
